Modifiers of Liver-Related Manifestation in the Course of NAFLD

Current Pharmaceutical Design
Patrik NasrMattias Ekstedt

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease affecting approximately 25% of the global population. There is a strong association between the severity of NAFLD and the components of the metabolic syndrome. NAFLD is also independently associated with cardiovascular disease and type 2 diabetes mellitus (T2DM). The progressive potential of non-alcoholic fatty liver disease (NAFLD) is indisputable today, and the histological spectrum of NAFLD ranges from isolated steatosis to nonalcoholic steatohepatitis (NASH), with risk of developing fibrosis and subsequent cirrhosis and hepatocellular carcinoma. There is a substantial inter-patient variation in disease progression, therefore, this review will focus on potential modifiers of fibrosis progression, development of liver cirrhosis, decompensation and liver-related mortality. The potential drivers of disease progression that is discussed are; T2DM and Insulin Resistance, body weight, alcohol consumption, genetics (including HFE and alfa-1-antitrypsin) as well as histological features predictive of disease progression.

Citations

May 1, 2020·Current Pharmaceutical Design·Amedeo Lonardo, Giovanni Targher
Aug 23, 2020·International Journal of Molecular Sciences·Daniela Maria TanaseMariana Floria
Apr 22, 2021·BMC Gastroenterology·Patrik NasrMattias Ekstedt

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Related Papers

World Journal of Gastroenterology : WJG
Hakan Fotbolcu, Elçin Zorlu
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
C Y ZhuJ G Fan
World Journal of Gastroenterology : WJG
Brandon J PerumpailAijaz Ahmed
Alimentary Pharmacology & Therapeutics
Paul Angulo
© 2021 Meta ULC. All rights reserved